3:20 PM
 | 
May 31, 2019
 |  BC Extra  |  Company News

May 31 Company Quick Takes: NMPA accepts two BeiGene applications, approves Hengrui's PD-1 inhibitor; and more

Editor's Note: This article was updated on May 31, 2019 at 4:10 PM PDT

NMPA accepts applications for BeiGene's tislelizumab, Abraxane
China's National Medical Products Administration has accepted an sNDA from BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) for tislelizumab to treat previously treated, locally advanced or metastatic urothelial carcinoma. The anti-PD-1 mAb is also under review in China for relapsed/refractory classical Hodgkin lymphoma. NMPA accepted BeiGene's supplemental import drug application for Abraxane paclitaxel in combination with gemcitabine for first-line treatment...

Read the full 294 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >